Asimov

Asimov is a Boston-based life sciences company that develops an integrated platform combining mammalian synthetic biology with computer-aided design tools to support the design and manufacture of advanced genetic therapies. The company serves biologic, cell therapy, gene therapy, and RNA therapy developers by providing engineered host cells, validated genetic parts libraries, and cloud-based design software. Asimov was founded in 2017 by Alec Nielsen (CEO), Chris Voigt (MIT), Doug Densmore (Boston University), and Raja Srinivas, with early backing from Andreessen Horowitz and DARPA, and its origins trace to academic work on genetic logic circuit design, including the 2016 release of Cello, a platform for automated genetic circuit design.

The company's stated mission is to apply the principles of computer-aided design — abstraction, standardization, characterization, and modeling — to genetic engineering, with the goal of making the discipline more precise and reliable. Asimov draws a parallel to how CAD transformed semiconductor, aerospace, and structural engineering over the past 50 years, and positions its Kernel platform as the first true CAD environment for biology.

Therapeutic Application Areas

• Biologics (CHO Edge): Integrates genetic tools and data-driven models to deliver protein titers of 8–12 g/L across modalities using CHO-based host cells.
• Cell Therapies (LV Edge): Provides stable cell lines and software design tools to enable lentiviral vector titers of up to 1×10⁹ TU/mL for therapeutic transgenes.
• Gene Therapies (AAV Edge): Offers end-to-end payload design and gene therapy production tools, achieving AAV titers of up to 6×10¹⁵ vg/L.
• RNA Therapies (RNA Edge): Supports programs from sequence design through wet lab validation, delivering high-confidence candidates within weeks.

Platform Components

• Engineered host cell lines: GMP-grade, highly characterized host cells for therapeutic production, supplied with supporting regulatory documentation.
• Genetic parts library: More than 1,000 experimentally validated genetic parts — including transposases, expression vectors, inducible systems, and tissue-specific promoters — available to control cell biology.
• Design software (Kernel): Cloud-based software for designing, simulating, and optimizing genetic systems across different cell types and applications.

Engagement and Partnering Models

• Platform transfer to customer lab: Asimov ships host cells and grants access to its software, enabling customers to conduct cell line development in-house. Customers use the software to design and optimize genetic constructs, transfect cells, generate stable cell lines, and perform data analysis.
• Full cell line development by Asimov: Customers request a producer cell line for a biologic or gene therapy; Asimov performs cell line development and process development at its own site, shares progress and data through its software, and ships clonal cell banks with process transfer to the customer's site.

Company Background and Foundations

• Asimov's scientific roots lie in the Voigt Lab at MIT and the Densmore Lab at Boston University, where co-founders developed the foundations of genetic logic circuit design.
• The 2016 Cello platform, developed with collaborators including NIST, demonstrated automated genetic circuit design using modular logic gates, standardized host cells, and algorithmic design and simulation software.
• Asimov is headquartered at 201 Brookline Avenue, Suite 1201, Boston, MA 02215.